OA11965A - Diphosphate salt of a 4"-substituted-9-deoxo-9a-homoerythromycin derivative and its pharmaceutical composition. - Google Patents

Diphosphate salt of a 4"-substituted-9-deoxo-9a-homoerythromycin derivative and its pharmaceutical composition. Download PDF

Info

Publication number: OA11965A
Authority: OA; OAPI
Prior art keywords: diphosphate; sait; water; ciaim; free base
Prior art date: 1999-06-30

Application number

OA1200100329A

Other languages

English (en)

Inventor

Douglas John Meldrum Allen

Robert John Rafka

Colman Brendan Ragan

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-30

Filing date

2000-06-13

Publication date

2006-04-12

2000-06-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-04-12 Publication of OA11965A publication Critical patent/OA11965A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 title abstract 4
239000001177 diphosphate Substances 0.000 claims abstract description 54
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims abstract description 54
235000011180 diphosphates Nutrition 0.000 claims abstract description 54
239000012458 free base Substances 0.000 claims abstract description 21
241000124008 Mammalia Species 0.000 claims abstract description 12
238000000034 method Methods 0.000 claims abstract description 8
206010037075 Protozoal infections Diseases 0.000 claims abstract description 7
230000001580 bacterial effect Effects 0.000 claims abstract description 7
208000035143 Bacterial infection Diseases 0.000 claims abstract description 5
230000000844 anti-bacterial effect Effects 0.000 claims abstract description 5
208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 5
125000006308 propyl amino group Chemical group 0.000 claims abstract description 4
239000003904 antiprotozoal agent Substances 0.000 claims abstract description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
239000004973 liquid crystal related substance Substances 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 9
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
235000011007 phosphoric acid Nutrition 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 4
239000003643 water by type Substances 0.000 claims description 4
238000003776 cleavage reaction Methods 0.000 claims description 3
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
238000003760 magnetic stirring Methods 0.000 claims description 3
239000012074 organic phase Substances 0.000 claims description 3
230000007017 scission Effects 0.000 claims description 3
230000006641 stabilisation Effects 0.000 claims description 3
238000011105 stabilization Methods 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
230000000842 anti-protozoal effect Effects 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
230000001747 exhibiting effect Effects 0.000 claims 2
239000004990 Smectic liquid crystal Substances 0.000 claims 1
238000001704 evaporation Methods 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229910052757 nitrogen Inorganic materials 0.000 claims 1
239000012071 phase Substances 0.000 claims 1
229910052698 phosphorus Inorganic materials 0.000 claims 1
238000000634 powder X-ray diffraction Methods 0.000 claims 1
238000000638 solvent extraction Methods 0.000 claims 1
239000003242 anti bacterial agent Substances 0.000 abstract description 2
230000000694 effects Effects 0.000 abstract description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
230000003389 potentiating effect Effects 0.000 abstract description 2
239000000243 solution Substances 0.000 description 11
150000001875 compounds Chemical class 0.000 description 8
239000013078 crystal Substances 0.000 description 8
238000002441 X-ray diffraction Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 6
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
QAUZNYGRSNDEAL-UHFFFAOYSA-N O.O.O.O.O.O.O.O.OP(O)(=O)OP(=O)(O)O Chemical compound O.O.O.O.O.O.O.O.OP(O)(=O)OP(=O)(O)O QAUZNYGRSNDEAL-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000010792 warming Methods 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960004099 azithromycin Drugs 0.000 description 1
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000047 product Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
235000019798 tripotassium phosphate Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
-1 élixirs Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

OA1200100329A 1999-06-30 2000-06-13 Diphosphate salt of a 4"-substituted-9-deoxo-9a-homoerythromycin derivative and its pharmaceutical composition. OA11965A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US14168199P	1999-06-30	1999-06-30

Publications (1)

Publication Number	Publication Date
OA11965A true OA11965A (en)	2006-04-12

Family

ID=22496734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100329A OA11965A (en)	1999-06-30	2000-06-13	Diphosphate salt of a 4"-substituted-9-deoxo-9a-homoerythromycin derivative and its pharmaceutical composition.

Country Status (42)

Country	Link
US (3)	US6465437B1 (fr)
EP (1)	EP1189913B1 (fr)
JP (1)	JP2003503506A (fr)
KR (1)	KR100442508B1 (fr)
CN (2)	CN1358188A (fr)
AP (1)	AP2001002370A0 (fr)
AR (1)	AR035551A1 (fr)
AT (1)	ATE286906T1 (fr)
AU (1)	AU772277B2 (fr)
BG (1)	BG65587B1 (fr)
BR (1)	BR0012091A (fr)
CA (1)	CA2376748C (fr)
CO (1)	CO5190679A1 (fr)
CZ (1)	CZ20014571A3 (fr)
DE (1)	DE60017399T2 (fr)
EA (1)	EA004235B1 (fr)
EC (1)	ECSP003555A (fr)
EE (1)	EE05068B1 (fr)
ES (1)	ES2233380T3 (fr)
GT (2)	GT200000105A (fr)
HN (1)	HN2000000090A (fr)
HR (1)	HRP20010919B1 (fr)
HU (1)	HUP0201693A3 (fr)
IL (1)	IL146408A0 (fr)
IS (1)	IS6159A (fr)
MA (1)	MA26745A1 (fr)
MX (1)	MXPA02000058A (fr)
MY (1)	MY133360A (fr)
NO (1)	NO20016221D0 (fr)
OA (1)	OA11965A (fr)
PA (1)	PA8496901A1 (fr)
PE (1)	PE20010287A1 (fr)
PL (1)	PL201891B1 (fr)
PT (1)	PT1189913E (fr)
SK (1)	SK286243B6 (fr)
TN (1)	TNSN00143A1 (fr)
TR (1)	TR200103834T2 (fr)
UA (1)	UA71013C2 (fr)
UY (1)	UY26221A1 (fr)
WO (1)	WO2001002414A1 (fr)
YU (1)	YU88701A (fr)
ZA (1)	ZA200110453B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6465437B1 (en) *	1999-06-30	2002-10-15	Pfizer Inc.	Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6791660B1 (en) *	2002-02-12	2004-09-14	Seiko Epson Corporation	Method for manufacturing electrooptical device and apparatus for manufacturing the same, electrooptical device and electronic appliances
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
WO2013013834A1 (fr)	2011-07-27	2013-01-31	Farma Grs, D.O.O.	Nouvelles formes cristallines de tulathromycine
CN106008622A (zh) *	2016-08-02	2016-10-12	海门慧聚药业有限公司	泰拉霉素新晶型及其制备
CN110885351A (zh) *	2019-12-17	2020-03-17	海门慧聚药业有限公司	泰拉霉素磷酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
SI9011409A (en) *	1990-07-18	1995-10-31	Pliva Pharm & Chem Works	O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
HN1998000086A (es) *	1997-06-11	1999-03-08	Pfizer Prod Inc	Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JP2003512290A (ja) *	1997-09-10	2003-04-02	メルクエンドカムパニーインコーポレーテッド	家畜抗菌剤としての８ａ−アザライド
UA70972C2 (uk) *	1998-11-20	2004-11-15	Пфайзер Продактс Інк.	13-членні азаліди і їх застосування як антибіотиків
HUP0201341A3 (en) *	1999-05-18	2003-03-28	Pfizer Prod Inc	Novel crystalline forms of a macrolide antibiotic, process for its preparation and pharmaceutical compositions containing it
US6465437B1 (en) *	1999-06-30	2002-10-15	Pfizer Inc.	Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition

2000
- 2000-05-18 US US09/574,160 patent/US6465437B1/en not_active Expired - Fee Related
- 2000-06-01 HN HN2000000090A patent/HN2000000090A/es unknown
- 2000-06-06 PA PA20008496901A patent/PA8496901A1/es unknown
- 2000-06-13 KR KR10-2001-7016939A patent/KR100442508B1/ko not_active Expired - Fee Related
- 2000-06-13 CA CA002376748A patent/CA2376748C/fr not_active Expired - Fee Related
- 2000-06-13 AP APAP/P/2001/002370A patent/AP2001002370A0/en unknown
- 2000-06-13 CN CN00809635A patent/CN1358188A/zh active Pending
- 2000-06-13 ES ES00931491T patent/ES2233380T3/es not_active Expired - Lifetime
- 2000-06-13 PL PL352900A patent/PL201891B1/pl unknown
- 2000-06-13 HU HU0201693A patent/HUP0201693A3/hu unknown
- 2000-06-13 UA UA2001129148A patent/UA71013C2/uk unknown
- 2000-06-13 AU AU49439/00A patent/AU772277B2/en not_active Ceased
- 2000-06-13 TR TR2001/03834T patent/TR200103834T2/xx unknown
- 2000-06-13 OA OA1200100329A patent/OA11965A/en unknown
- 2000-06-13 SK SK1892-2001A patent/SK286243B6/sk not_active IP Right Cessation
- 2000-06-13 CZ CZ20014571A patent/CZ20014571A3/cs unknown
- 2000-06-13 BR BR0012091-0A patent/BR0012091A/pt not_active IP Right Cessation
- 2000-06-13 YU YU88701A patent/YU88701A/sh unknown
- 2000-06-13 HR HR20010919A patent/HRP20010919B1/xx not_active IP Right Cessation
- 2000-06-13 WO PCT/IB2000/000785 patent/WO2001002414A1/fr not_active Ceased
- 2000-06-13 IL IL14640888A patent/IL146408A0/xx unknown
- 2000-06-13 JP JP2001507850A patent/JP2003503506A/ja active Pending
- 2000-06-13 EA EA200101178A patent/EA004235B1/ru not_active IP Right Cessation
- 2000-06-13 EE EEP200100699A patent/EE05068B1/xx not_active IP Right Cessation
- 2000-06-13 MX MXPA02000058A patent/MXPA02000058A/es active IP Right Grant
- 2000-06-13 CN CNA200710199182XA patent/CN101220067A/zh active Pending
- 2000-06-13 DE DE60017399T patent/DE60017399T2/de not_active Expired - Fee Related
- 2000-06-13 PT PT00931491T patent/PT1189913E/pt unknown
- 2000-06-13 EP EP00931491A patent/EP1189913B1/fr not_active Expired - Lifetime
- 2000-06-13 AT AT00931491T patent/ATE286906T1/de not_active IP Right Cessation
- 2000-06-16 CO CO00045176A patent/CO5190679A1/es not_active Application Discontinuation
- 2000-06-26 UY UY26221A patent/UY26221A1/es not_active Application Discontinuation
- 2000-06-27 PE PE2000000645A patent/PE20010287A1/es not_active Application Discontinuation
- 2000-06-28 TN TNTNSN00143A patent/TNSN00143A1/fr unknown
- 2000-06-28 MY MYPI20002923 patent/MY133360A/en unknown
- 2000-06-28 MA MA26011A patent/MA26745A1/fr unknown
- 2000-06-28 AR ARP000103255A patent/AR035551A1/es not_active Application Discontinuation
- 2000-06-28 GT GT200000105A patent/GT200000105A/es unknown
- 2000-06-28 GT GT200000105AK patent/GT200000105AA/es unknown
- 2000-06-30 EC EC2000003555A patent/ECSP003555A/es unknown
2001
- 2001-11-13 IS IS6159A patent/IS6159A/is unknown
- 2001-11-20 BG BG106123A patent/BG65587B1/bg unknown
- 2001-12-19 NO NO20016221A patent/NO20016221D0/no not_active Application Discontinuation
- 2001-12-20 ZA ZA200110453A patent/ZA200110453B/xx unknown
2002
- 2002-08-12 US US10/218,154 patent/US6861412B2/en not_active Expired - Fee Related
2004
- 2004-05-06 US US10/840,529 patent/US7297682B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2376748A1 (fr)	2001-01-11
EP1189913A1 (fr)	2002-03-27
GT200000105AA (es)	2001-12-20
EA200101178A1 (ru)	2002-06-27
HN2000000090A (es)	2001-04-20
JP2003503506A (ja)	2003-01-28
AR035551A1 (es)	2004-06-16
US20030092642A1 (en)	2003-05-15
WO2001002414A1 (fr)	2001-01-11
EE200100699A (et)	2003-02-17
IL146408A0 (en)	2002-07-25
ES2233380T3 (es)	2005-06-16
ZA200110453B (en)	2003-03-04
MY133360A (en)	2007-11-30
PL352900A1 (en)	2003-09-22
NO20016221L (no)	2001-12-19
CN101220067A (zh)	2008-07-16
PA8496901A1 (es)	2002-08-26
DE60017399T2 (de)	2006-03-30
TR200103834T2 (tr)	2002-05-21
BR0012091A (pt)	2002-04-02
ECSP003555A (es)	2002-01-25
EP1189913B1 (fr)	2005-01-12
YU88701A (sh)	2004-09-03
HRP20010919B1 (en)	2005-06-30
MA26745A1 (fr)	2004-12-20
TNSN00143A1 (fr)	2005-11-10
GT200000105A (es)	2001-12-20
SK18922001A3 (sk)	2002-04-04
SK286243B6 (sk)	2008-06-06
EE05068B1 (et)	2008-08-15
AP2001002370A0 (en)	2001-12-31
ATE286906T1 (de)	2005-01-15
PL201891B1 (pl)	2009-05-29
AU772277B2 (en)	2004-04-22
AU4943900A (en)	2001-01-22
PE20010287A1 (es)	2001-03-05
UA71013C2 (uk)	2004-11-15
KR20020016875A (ko)	2002-03-06
CO5190679A1 (es)	2002-08-29
MXPA02000058A (es)	2002-07-02
DE60017399D1 (de)	2005-02-17
HRP20010919A2 (en)	2003-02-28
PT1189913E (pt)	2005-04-29
US20040209826A1 (en)	2004-10-21
CN1358188A (zh)	2002-07-10
BG106123A (en)	2002-05-31
US7297682B2 (en)	2007-11-20
HUP0201693A3 (en)	2003-03-28
IS6159A (is)	2001-11-13
BG65587B1 (bg)	2009-01-30
EA004235B1 (ru)	2004-02-26
UY26221A1 (es)	2001-01-31
NO20016221D0 (no)	2001-12-19
CA2376748C (fr)	2006-03-14
US6861412B2 (en)	2005-03-01
HUP0201693A2 (en)	2002-10-28
KR100442508B1 (ko)	2004-07-30
CZ20014571A3 (cs)	2002-04-17
US6465437B1 (en)	2002-10-15

Publication	Publication Date	Title
DK2125850T3 (en)	2018-07-30	MACROCYCLIC POLYMORPHS, COMPOSITIONS INCLUDING SUCH POLYMORPHS, PROCEDURES FOR PREPARING AND USING THEREOF
FR2727969A1 (fr)	1996-06-14	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
OA11965A (en)	2006-04-12	Diphosphate salt of a 4"-substituted-9-deoxo-9a-homoerythromycin derivative and its pharmaceutical composition.
PL199434B1 (pl)	2008-09-30	Kryształ wodzianu czterosodowej soli P¹ P⁴-di(urydyno-5'-)czterofosforanu i sposób jego wytwarzania
WO1989004167A1 (fr)	1989-05-18	DERIVES A EFFET ANTIBACTERIEN DE 9a-ALLYLE ET 9a-PROPARGYLE DE 9-DESOXO-9a-AZA-9a-HOMOERYTHROMYCINE A
HK153696A (en)	1996-08-16	Pharmaceutical compounds
US2881163A (en)	1959-04-07	Process of preparing salts
JP2728482B2 (ja)	1998-03-18	マクロライド系抗生物質の精製法
HK1118294A (en)	2009-02-06	Diphosphate salt of a 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition
HK1047112A (en)	2003-02-07	Diphosphate salt of a 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition
KR20060128633A (ko)	2006-12-14	용매가 전혀 존재하지 않는 산 세포테탄 및 이를 수득하는방법
JP2572563B2 (ja)	1997-01-16	セファロスポリン中間生成物の新規安定な結晶形
HU176213B (en)	1981-01-28	Process for preparing a new crystallic modification of the sodium salt of 7beta-cyanacetylamino-3-acetoxymethyl-cef-3-em-4-carboxylic acid
SK83199A3 (en)	2000-05-16	Novel erythromycin derivatives, method of preparation and application as medicines
JPH0196190A (ja)	1989-04-14	６−０−アルキル−エリスロマイシンａ　サイクリック１１，１２−カーボネート
WO2006064299A1 (fr)	2006-06-22	Traitement industriel de clarithromycine associee a des taux calcules de produits secondaires
EA044465B1 (ru)	2023-08-29	Способы очистки изавуконазония сульфата
JPWO1999014225A1 (ja)	2002-08-20	抗真菌剤ｖ−２８−３ｍのアセトン付加体
HK1134096A (en)	2010-04-16	Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
HK1134096B (en)	2018-11-02	Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof